Page last updated: 2024-12-09

1-(2,6-dimethyl-1H-indol-3-yl)-2-(1-pyrrolidinyl)ethanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you're describing, 1-(2,6-dimethyl-1H-indol-3-yl)-2-(1-pyrrolidinyl)ethanone, is a synthetic molecule often called **Indoximod**. It's not a naturally occurring substance but has gained significant interest in research due to its potential therapeutic applications, primarily as an **immunomodulator**.

**Here's why it's important for research:**

* **Immune System Stimulation:** Indoximod acts as a **toll-like receptor 7 (TLR7) agonist**. TLR7 is a key component of the innate immune system, recognizing viral RNA and triggering immune responses. Indoximod essentially 'tricks' the immune system into thinking a viral infection is present, leading to the production of various immune cells and molecules that can fight infections and cancers.
* **Cancer Therapy:** This immune-stimulating property has made Indoximod a promising candidate for treating various cancers. It's currently being investigated in clinical trials for **advanced melanoma**, **non-small cell lung cancer**, and other types of tumors. The hope is that Indoximod can help the immune system target and destroy cancerous cells.
* **Antiviral Activity:** Indoximod's TLR7 agonistic activity also suggests potential applications in fighting viral infections. It's being researched for its potential to treat **viral hepatitis** and other viral illnesses.
* **Mechanism of Action:** Understanding how Indoximod works can lead to the development of new and improved immunotherapies. Scientists are actively studying the molecule's interactions with TLR7 and the downstream signaling pathways involved in activating the immune system.

**Overall:** Indoximod represents an exciting area of research with potential benefits for treating a wide range of diseases. Its ability to modulate the immune system, particularly through TLR7 activation, offers promising avenues for developing new therapies. However, it's crucial to note that research is ongoing, and the full scope of its applications and potential side effects are still being investigated.

Cross-References

ID SourceID
PubMed CID660165
CHEMBL ID1511622
CHEBI ID120959

Synonyms (11)

Synonym
MLS000037422 ,
smr000041084
CHEBI:120959
1-(2,6-dimethyl-1h-indol-3-yl)-2-pyrrolidin-1-ylethanone
AKOS005470088
STK539730
1-(2,6-dimethyl-1h-indol-3-yl)-2-(pyrrolidin-1-yl)ethanone
HMS2276C15
CHEMBL1511622
1-(2,6-dimethyl-1h-indol-3-yl)-2-(1-pyrrolidinyl)ethanone
Q27209167
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
thioredoxin glutathione reductaseSchistosoma mansoniPotency19.95260.100022.9075100.0000AID485364
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
VprHuman immunodeficiency virus 1Potency31.62281.584919.626463.0957AID651644
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]